25 / 59
Penson
11
;
may not be reproduced without
full permission from ASCO
®
and
the author of this poster
(QR) code with your smartphone
app to view a plain language
summary
eneral;
-being;
Figure 2. Association between longitudinal changes in HRQoL (FACT-P) and MFS
CI=confidence interval; EWB=emotional well-being; FACT-G=Functional Assessment of Cancer Therapy–General; FACT-P=Functional Assessment of Cancer Therapy–Prostate;
FAPSI=FACT Advanced Prostate Symptom Index; FWB=functional well-being; HR=hazard ratio; HRQoL=health-related quality of life; MFS=metastasis-free survival;
PCS=prostate cancer subscale; PCSP=prostate cancer subscale pain-related score; PSA=prostate-specific antigen; PWB=physical well-being; SWB=social/family well-being;
TOI=trial outcome index.
7)
9)
3)
4)
9)
0)
8)
2)
7)
8)
!
0.001
!
0.001
!
0.001
0.080
0.006
!
0.001
!
0.001
!
0.001
!
0.001
!
0.001
p-value
0.7
0.8
Domain
PWB
0.86 (0.81, 0.92)
FWB
0.94 (0.88, 1.01)
EWB
0.88 (0.78, 0.99)
SWB
0.99 (0.93, 1.07)
PCSP
0.92 (0.85, 1.00)
PCS
0.91 (0.86, 0.96)
FAPSI
0.84 (0.79, 0.91)
TOI
0.89 (0.83, 0.96)
FACT-G
0.95 (0.89, 1.00)
FACT-P total
0.93 (0.88, 1.00)
1.0
HR (95% CI)
!
0.001
0.091
0.041
0.887
0.047
!
0.001
!
0.001
0.002
0.066
0.039
p-value
0.9
1.1
Increased risk of metastasis
Decreased risk of metastasis
ASSOCIATION BETWEEN HEALTH-RELATED QUALITY OF LIFE
AND CLINICAL OUTCOMES IN PROSPER
Attard G, et al. J Clin Oncol 36, 2018 (suppl; abstr 5043)